The detection and quantification of lorazepam and its 3-O-glucuronide in fingerprint deposits by LC-MS/MS.
The use of fingerprints as an alternative biological matrix to test for the presence of drugs and/or their metabolites is a novel area of research in analytical toxicology. This investigation describes quantitative analysis for the benzodiazepine lorazepam and its 3-O-glucuronide conjugate in fingerprints following the oral administration of a single 2 mg dose of lorazepam to five volunteers. Creatinine was also measured to investigate whether the amount of drug relative to that of creatinine would help to account for the variable amount of secretory material deposited. Fingerprints were deposited on glass cover slips and extracted by dissolving them in a solution of dichloromethane/methanol, containing tetradeuterated lorazepam as an internal standard. The samples were evaporated, reconstituted with mobile phase and analysed by LC-MS/MS. Chromatography was achieved using an RP (C18) column for the analysis of lorazapem and its glucuronide, and a hydrophilic interaction column (HILIC) for the analysis of creatinine. Lorazepam and its glucuronide were only detected where ten prints had been combined, up to 12 h following drug administration. In every case, the amount of lorazepam glucuronide exceeded that of lorazepam, the peak amounts being 210 and 11 pg, respectively. Adjusting for creatinine smoothed the elimination profile. To our knowledge, this represents the first time a drug glucuronide has been detected in deposited fingerprints.
Goucher
Edward
E
Department of Forensic Science and Drug Monitoring, Pharmaceutical Science Research Division, King's College London, London, UK. edward.goucher@kcl.ac.uk
Kicman
Andrew
A
Smith
Norman
N
Jickells
Sue
S
D000328:Adult; D014151:Anti-Anxiety Agents / Q000737:chemistry*; D002853:Chromatography, Liquid / Q000295:instrumentation / Q000379:methods*; D003404:Creatinine / Q000032:analysis; D003878:Dermatoglyphics; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000032:analysis / Q000737:chemistry* / Q000378:metabolism; D008297:Male; D015394:Molecular Structure; D012867:Skin / Q000378:metabolism*; D053719:Tandem Mass Spectrometry / Q000295:instrumentation / Q000379:methods*; D055815:Young Adult
D014151:Anti-Anxiety Agents; D003404:Creatinine; D008140:Lorazepam; C031290:lorazepam glucuronide